[Abstract] Recently, we identified two host cell-derived proteins as novel stimulatory factors of influenza virus RNA replication process, termed "Influenza virus REplication Factor-2 (IREF-2)", from human nuclear extracts (NEs) by employing biochemical complementation assays (Sugiyama et al., 2015) .
3. Trypsinize the cells, resuspend in S-MEM + 5% calf serum (CS), and count the number of cells.
4. Adjust the cell density to ~2 x 10 5 cells/ml by adding S-MEM + 5% CS.
5. Place the cell suspension into a 500 ml-size spinner flask (sterilized), and incubate at 37 °C with gentle stirring by a magnetic stirrer (60-80 rotations/min).
6. Monitor the cell growth by daily counting the number of cells, and add fresh medium (S-MEM + 5% CS) to maintain cells at 3-6 x 10 5 cells/ml. When the volume of cell culture reaches to 500 ml, transfer the culture to a large-scale spinner flask (8 L-size) and maintain incubation at 37 °C. 8. Centrifuge the homogenate at 3,300 x g for 10 min at 4 °C, and remove the supernatant. The supernatant removed at this step can be saved as "S-100" cytoplasmic extracts (Dignam et al., 1983) , and utilized for other purpose (Matsumoto et al., 1993 ).
9. Re-centrifuge the remaining pellet (i.e., nuclei) at 14,000 x g for 20 min at 4 °C and remove the residual supernatant completely. ii. Pour off supernatant, resuspend the resin in water, and repeat at least 8-10 times to remove any unsettled fine.
iii. Suspend the resin in 0.2 M NaOH, allow to settle for 30 min.
iv. Pour off supernatant and repeat until pH of supernatant is above 10.
v. Wash the resin with water until pH of supernatant is below 8.
vi. Suspend the resin in 0.2 M HCl, allow to settle.
vii. Pour off supernatant and repeat until pH of supernatant is below 3.
viii. Wash the resin with water until pH of supernatant is about 5.
ix. Equilibrate the resins in buffer HG. If the PC resin is to be stored for longer than a week, add 0.1% sodium azide and store at 4 °C (never freeze). Wash the system (including a "sample loop") with pure degassed water.
ii. Connect the prepared PC column (10 ml bed volume) to the system without introducing air, and wash the system including the column with enough water. Ensure no leakage from the column during flow.
iii. Set degassed buffer HG as solvent A to inlet A and degassed buffer HGK as solvent B to inlet B, respectively.
iv. Wash the system with 100% solvent B (buffer HGK; 1 M KCl) and then equilibrate with 5% solvent B (i.e., 95% solvent A of buffer HG; 50 mM KCl). e. Make small aliquot(s) of each fractionated sample to avoid unnecessary freezing/thawing cycle in future, and freeze in liquid N2 and store at -80 °C.
f. Check the activity (i.e., stimulation activity for influenza virus RNA replication, termed as "IREF-2" in this protocol) involved in the PC-fractions by employing a cell-free viral RNA replication assay using small aliquot (see Figure 3 and Note 10).
Copyright Sugiyama and Nagata. This article is distributed under the terms of the Creative Commons Attribution License (CC BY 4.0). ii. Wash the column with 100% solvent B, and equilibrate with 5% solvent B (i.e., 95% solvent A).
b. Thaw the IREF-2 activity-positive fraction (total 9 ml in this protocol) of the PC column chromatography (i.e., the unbound "flow-through" fraction, see Figure 3 ) and centrifuge at 20,000 x g for 5 min at 4 °C to remove insoluble material.
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www.bio-protocol.org/e1934 Isocratic flow (0.5 ml/min) with 18 ml (2 volumes of the input) of 5% solvent B (i.e., 95% solvent A; final 0.05 M KCl), collect the eluate (1 ml/fraction; total 18 fractions).
ii. Change the valve position from "inject" to "load".
iii.
Isocratic flow (0.5 ml/min) with 7.8 ml (6 column volumes) of 15% solvent B (i.e., 85% solvent A; final 0.15 M KCl), collect the eluate (1 ml/fraction; total 8 fractions).
iv. Isocratic flow (0.5 ml/min) with 7.8 ml (6 column volumes) of 30% solvent B (i.e., 70% solvent A; final 0.3 M KCl), collect the eluate (1 ml/fraction; total 8 fractions).
v. Isocratic flow (0.5 ml/min) with 7.8 ml (6 column volumes) of 60% solvent B (i.e., 40% solvent A; final 0.6 M KCl), collect the eluate (1 ml/fraction; total 8 fractions). ii. Change the valve position from "inject" to "load".
iii. Linear gradient flow (0.5 ml/min) ranging from 25% to 80% of solvent B with 15 ml, collect the eluate (0.5 ml/fraction; total 30 fractions). ii. Change the valve position from "inject" to "load".
iii. Linear gradient flow (0.3 ml/min) ranging from 100% to 0% of solvent B (i.e., from 0%
to 100% of solvent A) with 12 ml, collect the eluate (0.75 ml/fraction; total 16 fractions). ii. Change the valve position from "inject" to "load".
iii. Linear gradient flow (0.5 ml/min) ranging from 3% to 100% of solvent B with 15.6 ml (12 column volumes), collect the eluate (0.65 ml/fraction; total 24 fractions).
www.bio-protocol.org/e1934 ii. Change the valve position from "inject" to "load".
iii. Linear gradient flow (0.4 ml/min) ranging from 35% to 70% with 12 ml, collect the eluate D. Identification of two polypeptides responsible for IREF-2 activity by mass spectrometry 1. Subject two Mono-Q fractions involving two candidate peptides, the fraction number 6 enriched with the peptide A and the fraction number 9 enriched with the peptide B (see Figure 4) , to 11.5% SDS-PAGE.
2. Visualize the peptides separated in the gel by using a glutaraldehyde-free silver staining kit (for MS analysis).
3. Excise the gel pieces containing the bands of the peptide A and B, respectively (by using a clean razor blade).
4. Tryptic digestion in the gel pieces, followed by mass analysis (MALDI-TOF MASS).
Data analysis
Finally, pp32 (peptide A) and APRIL (peptide B) were identified as peptides derived from IREF-2 by database search using MS-Fit program in Protein Prospector (University of California San Francisco; http://prospector.ucsf.edu/prospector/mshome.htm). Top 3 hits of each mass analysis were summarized in Table 1 . Observed mass (m/z) and theoretical mass for each digested peptide were summarized as "supplementary file 1 (http://elifesciences.org/content/4/e08939v2/supp-material1)" in the original article (Sugiyama et al., 2015) .
Table 1. Top 3 hit proteins identified by MALDI-TOF MASS analyses
